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Abstract:  Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disorder 
of the central nervous system with characteristic demyelinating lesions and axonal loss. MS 
accounts for the most common cause of neurological disability in young adults in the Western 
world. The clinical manifestations and the course of MS are highly variable. The early stage 
of the disease is usually characterized by attacks of neurological dysfunction with complete 
or incomplete recovery, however, with time disability accumulates in many patients. MS is 
believed to result from an interplay between susceptibility genes and environmental factors, 
one of which is smoking. Smoking, a worldwide epidemic, can be regarded as an important 
risk factor for MS particularly because of its modifiable nature in the quest to prevent or temper 
the disease course in MS as well as providing possible insights into MS pathogenesis. There 
are also reports that smoking may influence the symptoms and disease progression in patients 
with MS. The purpose of this article is to review the effects of smoking on MS symptoms and 
progression. We conclude that (1) although there are some early reports on worsening of MS 
symptoms by smoking, the existing evidence is insufficient to thoroughly assess the effects 
of smoking on the myriad of MS symptoms and (2) smoking seems to adversely influence 
disease progression in MS patients. We also discuss the potential biological mechanisms 
linking smoking and MS.
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Introduction
Multiple sclerosis (MS) is primarily a chronic inflammatory disorder of the central 
nervous system (CNS) in which focal lymphocytic infiltrations result in damage of 
myelin and axons.1 Affecting around 2.5 million individuals worldwide, MS is the 
most common neurological disability in young adults.2 Females are affected 2–3 
times more frequently than males and clinical symptoms typically first present in the 
third or fourth decade of life.1 The diagnosis of MS is based on finding evidence of 
CNS lesions that are disseminated in time and space. The exact cause of MS is still 
unknown; however, it is believed that the disease results from an interplay between 
environmental and genetic factors.1 Some suggested environmental factors include viral 
infections, sunlight exposure/vitamin D deficiency, diet, and cigarette smoking.3 A posi-
tive association between smoking and the risk of developing MS has been reported. In 
fact, smoking is considered as an important risk factor for MS because of the strength 
of the evidence, its modifiable nature in the quest to prevent or temper the disease 
course in MS as well as providing possible insights into MS pathogenesis.3 There are 
also reports that smoking may influence the symptoms and progression of the disease. Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Dovepress
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This article reviews the effects of smoking on the symptoms 
and progression of MS along with the possible biological 
mechanisms which may explain a link between smoking and 
MS. There are different types of tobacco   consumption such 
as smoking, snuffing, and chewing. The focus of this article 
is on tobacco smoking, the most common form of which is 
cigarette smoking.
Symptoms and course of MS
In MS, damage to myelin results in denuded axons that 
are no longer able to transmit action potentials efficiently 
within the CNS.4 Therefore, MS can produce a wide range 
of symptoms reflecting the functional anatomy of impaired 
nerve conduction at affected sites in the CNS.2 Symptoms 
may include visual, motor, sensory, ataxic, autonomic, 
  cognitive, and others. About 80% of patients present with an 
acute episode indicative of CNS demyelination affecting one 
(or occasionally several) sites known as clinically isolated 
syndrome (CIS).1 With time, around 30%–70%5,6 of people 
with CIS (possible .80% if an abnormal baseline magnetic 
resonance imaging [MRI] is present)6 will have a subsequent 
relapse and thus convert to relapsing-remitting MS (RRMS) 
which is the most common form of the disease.5 RRMS 
is characterized by relapses or exacerbations followed by 
complete or incomplete remissions. The majority of patients 
with RRMS will eventually enter a progressive phase over 
time known as secondary progressive MS (SPMS). About 
20% of patients with MS experience a continuous worsening 
from onset with no preceding relapse known as primary 
progressive MS (PPMS).1
MS as an inflammatory disease
The sequence of events that initiate MS is not yet known 
and more than one pathogenetic mechanism is likely to 
contribute to tissue injury.4 However, it is largely believed 
that inflammation, at least in part mediated by autoimmunity, 
drives the pathogenesis of MS.7 One of the earliest events 
in the pathogenesis of MS is the migration of autoreactive 
T cells (directed against components of myelin) across the 
blood–brain barrier (BBB), the vascular shield which helps 
to regulate and protect the microenvironment of the brain.1 
Within the CNS and upon recognition of myelin-derived 
peptides on major histocompatibility complex molecules 
on the surface of antigen presenting cells, autoreactive T 
cells become reactivated and contribute to initiating inflam-
matory cascades by producing cytokines and chemokines, 
and recruiting other immune cells such as macrophages 
and B lymphocytes into the lesions.7,8 Endothelial adhesion 
molecules mediate the recruitment of immune cells into the 
CNS, and proteases particularly matrix metaloproteinases 
facilitate the migration of inflammatory cells into and within 
the CNS.7 Chronic CNS inflammation leads to demyelina-
tion and subsequent axonal damage. There is also evidence 
of axonal damage in the early stages of MS,9 and it could 
be implied both through pathological and epidemiological 
studies that axonal damage may occur independently of 
inflammation in MS.10–14 Other recent studies, however, sug-
gest that axonal injury is pathologically invariably associated 
with inflammation, especially in progressive MS,15 and that 
demyelination contributes to axonal density with a greater 
magnitude in PPMS compared with SPMS.16 Therefore, 
it remains to be determined if inflammation is primary or 
secondary to a neurodegenerative process in MS brains.17 
In addition, pathogenic heterogeneity in immune effector 
mechanisms involved in MS lesion formation has been 
reported,18 although this was challenged by another study.19
Epidemiologic considerations
More than 1.3 billion people smoke cigarettes worldwide, and 
each year, about 30 million people become new smokers.20,21 
Tobacco smoking is one of the main preventable causes of 
chronic disease and death. Smoking, as an environmental 
factor, is associated with increased risk of some autoim-
mune diseases such as rheumatoid arthritis, systematic lupus 
erythematosus, Graves’ hyperthyroidism, primary biliary 
cirrhosis, and possibly MS.22 It has also been shown that 
individuals with disabilities are more likely to have ever 
smoked and to be current smokers.23
A positive association between smoking and risk 
of MS has been suggested in some large prospective 
cohorts including the United Kingdom’s Oxford Family 
Planning Association Study, the Royal College of General 
Practitioners’ Oral Contraceptive Study, the General Practice 
Research Database Study, and the USA’s Nurses Health Study 
and Nurses Health Study II.3 A summary estimate showed 
a relative risk of 1.6 (95% CI, 1.3–1.9) for the development 
of MS in heavy smokers.3 In addition, children exposed to 
parental smoking at home have been found to have a higher 
risk of childhood-onset MS.24 Although confounding cannot 
be excluded, the existing evidence suggests that smoking 
does increase the risk for MS.3 According to recent reports, 
there is an alarming rise in the rate of smoking among young 
women worldwide.25 This is while women are at increased 
risk of developing MS compared with men and there are even 
some reports that female to male sex ratio in MS has increased 
over the last decades.26,27 It remains to be investigated whether Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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the increase in female smokers is linked with the increase in 
female to male ratio in MS patients.
Smoking and acute worsening  
of MS symptoms
Tobacco smoking was recognized, as early as the 19th 
century, as a cause of bilateral optic neuropathy.28 It was 
suggested in a self-report-based case series from the 1960s 
that during an MS relapse, patients appear to be unusually 
sensitive to the central effects of smoking during or shortly 
after smoking.29 This may result in accentuation of the cerebral 
symptoms such as mental confusion, blurred or double vision, 
vertigo and or ataxia, paresthesia, and motor weakness as 
well as general symptoms such as lassitude and fatigue.29 In 
a study assessing the effect of smoking on the recovery of 
visual function after an attack of optic neuritis (a common 
presentation of MS in which inflammation of the optic nerve 
causes unilateral painful blurring or loss of vision), heavy 
smokers were found to have a higher incidence of red/green 
color vision defects than nonsmokers.30 A transient wors-
ening of upper extremity motor performance immediately 
after smoking has also been described in MS patients.31 An 
explanation for the increased sensitivity to cigarette smok-
ing in MS patients could be that a compromised CNS with 
limited reserve may have increased vulnerability to altera-
tions in its state of balance.31 Yet, a thorough and systematic 
investigation of the effects of smoking on MS symptoms 
remains to be done.
Smoking and chronic  
progression of MS
A summary of the studies which have examined the 
relationship between smoking and MS progression is 
shown in Table 1. Cigarette smoking has been suggested to 
adversely influence the progression of MS and accelerates 
transition from a relapsing-remitting course to a progres-
sive course.32–35 The largest study to date investigating the 
effects of smoking on MS progression included 1,465 MS 
patients,35 and found that current smokers were more than 
twice as likely to have PPMS than people with MS who 
never smoked. This was supported by another study which 
not only showed that MS patients who ever smoked were 
twice as likely to have the progressive form of the disease, 
but also reported that people with early smoking debut 
(#15 years of age) were more likely to be diagnosed with 
progressive disease.32 Recently, smoking has been reported 
to be associated with some MRI markers of disease pro-
gression such as increased lesion burden and greater brain 
atrophy.36 Smoking has also been shown to be a risk factor 
for conversion from CIS to clinically definite MS.37 In a study 
in Groningen, the Netherlands, smoking was not associated 
with the rate of conversion from RRMS to SPMS or with 
time from MS onset to fixed disability milestones (as mea-
sured by the Expanded Disability Status Scale [EDSS]).38 
The reason for the conflicting result between this study and 
the other studies is not clear; however, a potential source of 
bias might relate to the Groningen’s study setting (hospital-
based) and its retrospective nature; a substantial proportion 
of patients had died or could not be contacted to complete 
the smoking questionnaire which was sent out over 20 years 
after recruitment of the first patients into the database.35 In 
a 3-year prospective Tasmanian cohort study (Australia), 
smoking was positively associated with the progression of 
clinical disability, but was not associated with the likelihood 
of developing a relapse among RRMS patients.33 In the 
same study, smoking was associated with an increased risk 
of a progressive course at MS onset rather than a relapsing-
remitting course. In summary, the majority of the studies 
which have investigated the relationship between smoking 
and MS progression suggest that smoking adversely influ-
ences the progression or course of the disease.
Potential biological mechanisms 
linking smoking and MS
A burning cigarette generates more than 4,500 chemical 
compounds many of which have various toxic, mutagenic, 
and carcinogenic effects.39 Moreover, compounds found in 
cigarette smoke go through complex chemical reactions.40 
It is not clear how smoking may affect MS symptoms and 
progression, or increase the risk of developing MS. However, 
some potential mechanisms, briefly reviewed below, can be 
suggested.
Chronic cyanide intoxication
Inhaled tobacco smoke is a major source of hydrogen 
cyanide.41 The levels of cyanide and its main metabolite, 
thiocyanate,42 are strongly correlated with the amount of 
smoking.42 Cyanide has been shown to induce selective 
demyelination in animal models.43–49 Demyelinative lesions 
were produced more successfully if repeated rather smaller 
doses of cyanide were administered, than one single large 
dose.50 Corpus callosum is an area of white matter susceptible 
to cyanide damage.51 Interestingly, the corpus callosum is 
also fairly likely to be attacked in MS.52 Considering all 
these findings, it is possible that smoking affects MS through 
cyanide encephalopathy.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Dysregulation of the blood  
brain barrier
Dysregulation of the BBB and transendothelial migration 
of autoreactive lymphocytes might be among the   earliest 
abnormalities seen in the disease process of MS and 
appear to parallel the release of inflammatory cytokines/
chemokines.1,53 Nicotine has been shown to increase local 
cerebral microvascular blood flow54,55 and to raise the 
influx of permeable solutes across the BBB in rats.56 In 
fact, nicotine leads to changes in BBB permeability via 
the modulation of tight junction proteins.57 It is, therefore, 
possible that smoking be related to MS through direct 
effects of nicotine or other cigarette smoke components on 
the BBB.34,42 Recently, the role of nicotine in increasing the 
risk of developing MS among smokers has been questioned 
by a case–control study showing that tobacco smoking, but 
not Swedish snuff (also containing nicotine) elevates the 
risk of MS.58
Immunomodulatory effects
Cigarette smoke may have mixed effects on the immune 
system. Nicotine, a major constituent of cigarette smoke, 
has been shown to suppress the T-cell response,59 and 
to affect the differentiation, phenotype, and function of 
antigen presenting cells.60–62 However, nicotine might 
also have therapeutic potential as a neuroprotective and 
anti-inflammatory agent.39 In addition, tobacco glycoprotein, 
a polyphenol-rich glycoprotein purified from tobacco leaves 
and present in cigarette smoke condensate, has been shown 
to stimulate the proliferation of human peripheral T cells and 
the differentiation of B cells.63 In the murine experimental 
autoimmune encephalomyelitis (EAE) model of MS, 
nicotine exposure was shown to delay and attenuate CNS 
inflammation and autoimmune responsiveness to myelin 
antigen.64 Another component of cigarette smoke, acrolein, 
has been associated with immunosupression and proposed 
to produce neurodegeneration.32 Cigarette smoking has also 
been associated with increased expression of Fas (a cell 
surface molecule with an important role in immune homeo-
stasis and cytotoxic activity) on B and CD4+ T lymphocytes.65 
In addition, cigarette smoking has antiestrogenic effects 
which may affect the T helper 1/T helper 2 balance.36 An 
immunomodulatory link can be hypothesized between MS 
and smoking; however, the involved mechanisms are not yet 
clear. In addition, the qualitative and quantitative aspects 
of the effects of smoking on the immune system might be 
related to smoking duration, as well as the sex and ethnicity 
of the studied subjects.39
Inflammatory effects
Cigarette smoke has been reported to have inflammatory 
effects such as increasing peripheral leukocyte counts, and 
recruitment of polymorphonuclear cells, monocytes, and 
macrophages.22 It has also been shown to increase levels of 
C-reactive protein (CRP), interleukin-6 (IL-6), serum inter-
cellular adhesion molecule 1 (ICAM-1), and E-selectin.22 
CRP and IL-6 are important inflammatory markers in auto-
immune diseases,66,67 and ICAM-1 and E-selectin are two 
endothelial adhesion molecules whose CNS expression may 
be up-regulated in MS to facilitate the entry of T cells into 
the CNS.4 It is thus possible that smoking affects MS through 
its inflammatory properties.
Complement activation plays an important role in the 
inflammatory response. A possible role for the complement 
system in MS has been proposed based on the demonstration 
of complement activation products in the MS brain and 
biological fluids.68 Complement component 3 (C3) deposits 
have been described in the brains of MS patients.69 Increased 
levels of serum complement component 5b-9 (C5b-9, the 
“terminal membrane attack complex”) have been reported in 
the cerebrospinal fluid (CSF) of MS patients during attacks. 
These levels have also been shown to correlate with the 
degree of neurological disability.70 However, it has been 
shown that during demyelination, activation of complement 
and C5b-9 assembly may have neuroprotective effects by 
protecting oligodendrocytes from apoptosis.70 Cigarette 
smoke can affect complement activation by increasing 
CRP levels and inducing C3a and C5a.71,72 It can thus be 
hypothesized that smoking may influence the role of comple-
ment in the inflammatory response in MS patients, although 
the exact mechanism(s) remain to be determined.
Nitric oxide
Nitric oxide (NO) is a free radical signaling molecule with 
a complex biochemistry produced from the amino acid 
arginine by the enzymatic action of NO synthases (NOS).73 
In addition to its role in regulating vessel tone, NO plays an 
important role in host defense and immunity including the 
modulation of inflammatory responses.74 NO has also been 
reported to cause axonal degeneration or block axonal con-
duction especially in physiologically active or demyelinated 
axons.75–77 Axonal degeneration makes a major contribution 
to permanent neurological disability in MS. Axons undergo 
degeneration particularly at the site of the inflammatory 
damage, suggesting that locally produced inflammatory 
factors, such as NO may play a role in mediating axonal 
degeneration in MS.75 iNOS is the high-output isoform of Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
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NOS.73 The codistribution of iNOS and nitrotyrosine (the 
product of peroxynitrite-mediated nitration of tyrosine) in 
active MS lesions has been demonstrated.78 iNOS has been 
shown to be expressed in multiple cell types in active MS 
lesions, and astrocyte iNOS has been suggested to contribute 
to vasodilation and damage to the BBB besides its immuno-
regulatory role.79 Elevated levels of NO metabolites in the 
CSF have been reported in MS and were found to correlate 
with the volume of gadolinium-enhanced lesions on MRI.80 
Cigarette smoke contains various free radicals including 
NO.81 Increased NO plasma levels in smokers have also 
been reported in several studies,82–84 although not confirmed 
in all studies.85 It might thus be hypothesized that smoking 
may increase NO concentration at sites of MS inflammatory 
lesions and contribute to axonal degeneration.34
Infections
It is well established that smoking increases the frequency 
and persistence of respiratory infections.86 An increased 
risk of MS exacerbations during respiratory infections has 
been reported.87–90 It has also been found that exacerbations 
around the time of a clinical infection lead to more 
sustained neurological damage than noninfection-associated 
exacerbations.91 An association between Chlamydia 
pneumonia (C pneumonia) infection and MS has been 
described,92,93 although not confirmed.94,95 C pneumonia-spe-
cific antibodies have been found to be higher in smokers than 
in nonsmokers.96,97 Smoking, therefore, could be linked to MS 
by increasing respiratory infections. Furthermore, a positive 
association between levels of antibodies to Epstein-Barr virus 
(EBV), a virus which has been repeatedly associated with 
MS in epidemiological and serological studies,98 and tobacco 
smoking has been reported.99 Recently, the immunoglobulin 
G antibody to EBV nuclear antigen 1 has been suggested as 
a marker of disease activity based on the correlation between 
antibody levels and gadolinium-enhancing lesions on brain 
MRI of MS patients.100
Modulation of matrix metalloproteinase
Matrix metaloproteinases are important contributors to 
the inflammatory damage at the level of the BBB in MS 
pathogenesis.101 They enhance the migration of autoreactive 
immune cells into CNS by degrading extracellular-
matrix   macromolecules.4 An increased serum level of 
metalloproteinase 9 (gelatinase B) in MS patients has been 
shown in some studies.101 This increase was found to be 
associated with more gadolinium-enhancing MRI lesions.102 
Cigarette smoking was also found to be associated with an 
elevation in serum metalloproteinase 9 levels.103 It may thus 
be speculated that smoking may affect MS by modulation of 
matrix metalloproteinase 9.
Iron overload
Iron is essential for myelin formation, function of the 
immune effector cells, and oxidative phosphorylation.104 
The importance of iron for brain function is reflected by 
the presence of receptors for transferrin on brain capillary 
  endothelial cells.105 Iron is also thought to contribute to 
oxidative damage in pathological conditions through 
catalyzing the formation of hydroxyl radicals,106,107 and 
causing secondary initiation of lipid peroxidation.108,109 
  Oxidative damage has been implicated in several   neurological 
diseases including MS. Chronic smoking can lead to iron 
overload. In fact, tissue hypoxia from smoking results in 
erythrocytosis and increased production of erythropoietin 
which consequently increases the red cell mass.110 This in 
turn augments cell turnover and the number of red blood 
cells destroyed, resulting in iron overload.111 Cigarette 
smoke also contains toxic heavy metals such as mercury, 
cadmium, manganese, and lead.112,113 In addition to potential 
neurotoxicity,114 accumulation of these toxic metal species 
may result in disturbance of iron metabolism in astrocytes 
and in the brain.115 Astrocytes are specialized to serve as 
depots of toxic metals,116 and divalent metals have been 
shown to compete with ferrous iron (Fe2+) for the divalent 
metal transporter 1, a major Fe2+ transporter mediating 
cellular iron uptake.115 Therefore, these metals have the 
potential to dysregulate iron metabolism in the brain. Some 
lines of evidence suggest a role for iron in MS inflammation. 
Significant increases in mean serum ferritin in MS patients 
over controls have been reported.104,117 Iron overload in MS 
plaques has been demonstrated in vivo by MRI.118 Also high 
iron concentrations have been found in oligodendrocytes, 
myelin, reactive myelin, and macrophages in MS lesions.119,120 
The cause of iron accumulation in MS is unknown and it 
is not clear whether iron overload leads to the damage or 
results from the damage in MS.104 Although further studies 
are needed to investigate the role of iron in MS pathogenesis, 
it may be conceivable that cigarette smoking affects MS by 
contributing to iron overload.
venous pathology
A topographic correspondence between the MS plaque 
and the cerebral venous system has been reported 
in postmortem neuropathological studies and MR 
venography.121–123 Histologic examination of the involved Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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veins has shown aspects of impaired venous drainage such 
as perivenous iron deposits and fibrin cuffs, particular to 
chronic venous insufficiency.124 Recently, a high incidence 
of chronic cerebrospinal venous insufficiency (CCSVI), a 
vascular picture characterized by the stenosis of the main 
extracranial cerebrospinal veins, the jugular and azygous 
system, and by the opening of substitute circles, has been 
described in MS patients by Zamboni et al123,125 (although 
the prevalence of smoking which could represent a 
confounding factor was not reported). Some discrepancies 
in the prevalence of CCSVI have been reported, in MS cases 
and healthy controls alike, between Zamboni et al’s Italian 
study vs Zivadinov et al’s126 North American (Buffalo) 
study. Indeed, this field of investigation is expanding 
rapidly, further clarification of the possible association or 
dissociation between MS and CCSVI is likely forthcoming. 
Smoking is reported to be significantly associated with 
lower limb venous insufficiency. The mechanisms leading 
to harmful effects of tobacco on the venous system are still 
not elucidated.127 However, cigarette smoking is believed to 
be a major factor in hypoxia through carbon monoxide and 
NO fixation in hemoglobin.127,128 It has been hypothesized 
that the effect of hypoxia on the functional state of the 
endothelium can be the starting point of a cascade of 
events leading to disorganization of the vessel typical 
of venous pathologies such as varicose veins. Hypoxia 
activates the endothelial cells, resulting in the production of 
proinflammatory factors within the vessel wall, increased 
capillary permeability and local inflammatory changes.129 
Endothelial basal lamina has been found thickened in 
heavy smokers and the thickening contained fibronectin.130 
It has also been reported that heavy smokers have impaired 
release of endothelium-derived relaxing factor in response 
to bradykinin and calcium ionophore. This impairment 
may increase vasomotor tone and smooth muscle prolifera-
tion in veins.131 Even the implication of a developmental 
origin in venous anomalies seen in CCSVI132 does not 
exclude the possibility that smoking could contribute to 
the venous flow abnormalities. It can thus be speculated 
that smoking may be related to venous MS hypothesis 
through harmful effects of tobacco on the venous system 
and its hemodynamics.
vitamin D
A link between vitamin D and MS has been supported by 
several lines of evidence including lower prevalence of MS 
where there is more sun, reduced risk of MS with adequate 
sunlight or vitamin D supplementation, and association of 
lower levels of vitamin D with greater risk of relapse.133 
A population-based survey in Switzerland showed that female 
current smokers had lower dietary intake of vitamin D than 
nonsmokers (1.92 µg/day in heavy smokers vs 2.39 µg/day in 
never smokers; P = 0.0003).134 Another cross-sectional study 
on females in Denmark showed that smokers as compared 
with nonsmokers had significantly reduced levels of 25(OH) 
vitamin D and 1,25(OH)2 vitamin D.135 Although several 
potential confounders may explain why smokers may differ 
from nonsmokers with respect to serum 25-hydroxyvitamin 
D levels, it can be speculated that smoking may contribute 
to the potential adverse effects of vitamin D deficiency in 
MS patients. Low serum 25(OH) vitamin D levels or low 
levels of sunlight might also contribute to an increased risk 
of upper respiratory tract infections and hence elevate the 
risk of an MS relapse.136
Other lifestyle factors  
and comorbidities
Smokers appear more likely to have coexisting comorbidities 
or engage in other lifestyle habits which might confound the 
relationship between smoking and MS. For instance, tobacco 
smokers are more likely to consume alcohol and caffeine and 
exercise less.137,138 A higher intake of caffeine-containing 
beverages, such as tea or coffee, in the period from infancy 
to adolescence, has been reported in MS cases compared 
with controls.139 Consumption of hard liquor, but not wine 
or beer, was significantly associated with an increased risk 
of developing MS.140 Although a questionnaire study showed 
that alcohol consumption was associated with lower disability 
scores,141 reverse causation cannot be ruled out, with perhaps 
reduced mobility and worsening bladder problems limiting 
a person’s desire to drink.
Higher levels of exercise have been associated with 
lower disability scores and improved cognition in MS.142 
Although causation again has yet to be shown, exercise 
might confound the relationship between smoking and MS. 
The diet of smokers has also been reported as being less 
healthy, characterized by a lower intake of vegetables, fruits, 
vitamins, dietary fiber, and polyunsaturated fat compared 
with nonsmokers.138,143 Some ecological studies have sug-
gested that diets high in animal/saturated fat and low in 
polyunsaturated fats may increase the risk of MS.3 Although 
a prospective study of dietary fat found neither animal nor 
saturated fats to be associated with an increased risk of MS. 
However, a nonsignificant, reduced risk of MS was associated 
with a higher intake of n-3 polyunsaturated linolenic acid.144 
Slight decreases in relapse rate and relapse severity were Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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associated with ω-6 fatty acids in some small studies.145 
No significant associations between risk of MS and intakes 
of fruits, vegetables, vitamin C, vitamin E, or multivitamin 
supplements have been found.146
Some associations between body mass index (BMI) and 
smoking have been described. Although mean BMI tended 
to be lower in smokers when compared with nonsmokers, 
an increased level of smoking was found to be positively 
associated with BMI among smokers, particularly in men.147 
In addition, obese adolescents have been found to have an 
increased risk of developing MS.148 Smokers appear at greater 
risk of comorbidities such as depression.149 High rates of 
depression have also been described in MS patients with a 
lifetime prevalence as high as 50%.150 Comorbidities such as 
vascular and mental comorbidities (including depression) and 
obesity were associated with a greater degree of disability at 
MS diagnosis and longer delays in the time between onset 
symptoms and diagnosis.151 Smoking is a risk factor for 
many vascular disorders. Vascular comorbidities have also 
been found to increase the risk of disability progression in 
MS.152 Further studies are needed to investigate how smok-
ing may interact with lifestyle factors and comorbidities in 
MS patients.
Apoe polymorphism modulation
Apolipoprotein E (ApoE), is an important carrier in 
transporting lipid, a major constituent of myelin. ApoE has 
been suggested to have a significant role in remodeling and 
repair of nerve tissue, and in modifying systemic and brain 
inflammatory responses.153,154 It is controversial whether 
ApoE polymorphism influences MS susceptibility or clinical 
severity. The risk associated with the ApoE polymorphism has 
been reported to be modulated by smoking in several diseases 
such as Alzheimer's disease.155 Although many tobacco 
ingredients or smoke-related metabolites have toxic effects 
on CNS, nicotine might have some potential neuroprotective 
and anti-inflammatory properties.39 Nicotine has been sug-
gested to have systematic immunosuppressive effects, and to 
inhibit microglial activation and leukocyte recruitment dur-
ing inflammatory processes.154 The main mediators of these 
effects are α7 nicotinic cholinergic receptors. A protective 
influence of smoking on disease progression in female MS 
patients carrying the ApoE E4 isoform has been reported.154 
Although this finding needs confirmation, authors speculated 
that in MS patients, smoking may counterbalance the ApoE 
E4-associated promotion of brain tissue damage by facilitat-
ing nicotinic cholinergic function.154
Advanced glycation end products (AGes) 
and their receptors
AGEs are a complex and heterogeneous group of reactive 
compounds formed from the nonenzymatic reaction of 
reducing sugars with the free amino groups of proteins, 
lipids, and nucleic acids.156 AGEs may bind to specific cell 
surface receptors such as the receptor for advanced glycation 
end products (RAGE), generate reactive oxygen species, 
and form crosslinks.157 RAGE is present on lymphocytes, 
mononuclear phagocytes, and vascular endothelial cells.158 
Besides AGEs, RAGE can also bind to other ligands such 
as amyloid β-peptide, S100 proteins, and amphoterin.159 
Ligand/RAGE interactions may lead to enhanced production 
of proinflammatory cytokines through the activation of many 
cell signaling pathways.160 Enhanced expression of RAGE 
has been found in neurons and inflammatory cells in immu-
nohistological studies of spinal cord tissue of MS patients 
compared with healthy controls.161 In addition, blockage of 
RAGE has been shown to suppress EAE.161 Soluble RAGE 
(sRAGE) is an isoform of RAGE that is believed to act as a 
decoy, preventing deleterious effects of AGE/RAGE signal-
ing by binding to RAGE ligands.162 Serum levels of sRAGE 
were shown to be significantly lower in MS patients compared 
with healthy controls.160 These findings may imply a potential 
role for the RAGE axis in the pathogenesis of MS. Tobacco-
derived reactive glycation products capable of promoting 
AGE formation have been identified in tobacco smoke, and 
serum AGE levels were found to be significantly higher in 
cigarette smokers than in nonsmokers.163 Based on these lines 
of evidence, it can be hypothesized that smoking may affect 
MS through the AGE–RAGE axis. This could be a potential 
avenue for future research.
Conclusions and future directions
The majority of studies investigating the influence of smoking 
on disease progression or development of the progressive 
course in MS have shown a significantly adverse effect of 
smoking on different outcome measures. Smoking should 
thus be considered as a modifiable risk factor for MS 
progression. Although it remains to be investigated whether 
smoking cessation (aside from the well recognized other 
health benefits) will actually slow down the more rapid MS 
progression associated with smoking, and how long this effect 
might take place once a person quits. Whether exposure to 
secondhand smoke has the same negative effects on MS pro-
gression is not yet known, although it may modify (increase) 
the risk of developing childhood MS.24 Possible worsening Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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of MS symptoms has been associated with smoking, but 
these findings need to be confirmed and the possible impact 
of smoking on the vast myriad of MS symptoms further 
evaluated. Further studies are needed to investigate the 
“dose response” (acute vs chronic) effects of smoking and 
MS. In addition, reverse causality should be considered, as 
MS onset or MS symptoms might   influence smoking habits. 
It also remains to be assessed whether smoking may affect 
an MS patient’s response to immunomodulatory therapy. 
Several potential biological mechanisms describing how 
smoking may be linked to MS can be suggested; however, 
the   association between smoking and MS is subjected to 
numerous confounders, as mentioned throughout this review, 
making it difficult to verify the actual nature of the associa-
tion, and how or whether it truly affects disease activity or 
progression. A better understanding of the mechanisms 
underlying the possible links between smoking and MS may 
provide new insights into the etiology and the pathogenesis 
of MS.
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